NEWS & COMMENTS

PROHOST    FILTER

   TODAY’S MOVES

ISIS (ISIS): Read posted news.

ILLUMINA (ILMN):  Stock will be hit on news that the firm decided to pay $600 million to acquire Solexa.

READ MORE: Illumina Signs Definitive Agreement to Acquire Solexa

AMGEN (AMGN): Excellent news on Enbrel

READ MORE: Data Shows ENBREL Provides Sustained Clinical Improvements for People with Ankylosing Spondylitis for up to Three Years

MEDAREX (MEDX): The firm announced that it expects to receive an undisclosed milestone payment from its licensing partner, Amgen Inc., for the advancement of an antibody into clinical trials. The antibody was developed using Medarex's UltiMAb(R) technology and is the fourth UltiMAb-derived antibody in clinical development by Amgen. Medarex may receive future milestone payments and royalties should this product candidate progress through clinical development and to the market.

READ MORE: Medarex to Receive Milestone Payment from Amgen

IDERA IDP): The firm presented a novel class of compounds which act as antagonists of specific Toll-Like Receptors (TLR). In preclinical studies, these antagonists have been shown to block immune activation through TLR7, 8, and 9, as evaluated by use of agonists specific to these receptors. The antagonists have been shown to be specific for TLR7, 8, and 9, as immune activation by agonists to other TLRs was not blocked.

Prohost is independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at: http://www.sec.gov/consumer/cyberfr.htm